Literature DB >> 20606136

Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry.

Joshua M Stolker1, Kevin F Kennedy, Jason B Lindsey, Steven P Marso, Michael J Pencina, Donald E Cutlip, Laura Mauri, Neal S Kleiman, David J Cohen.   

Abstract

BACKGROUND: Prediction of restenosis after percutaneous coronary intervention (PCI) remains challenging, and existing risk assessment algorithms were developed before the widespread adoption of drug-eluting stents (DES). METHODS AND
RESULTS: We used data from the EVENT registry to develop a risk model for predicting target lesion revascularization (TLR) in 8829 unselected patients undergoing DES implantation between 2004 and 2007. Using a split-sample validation technique, predictors of TLR at 1 year were identified from two thirds of the subjects (derivation cohort) using multiple logistic regression. Integer point values were created for each predictor, and the summed risk score (range, 0 to 10) was applied to the remaining sample (validation cohort). At 1 year, TLR occurred in 4.2% of patients, and after excluding stent thrombosis and early mechanical complications, the incidence of late TLR (more likely representing restenosis-related TLR) was 3.6%. Predictors of TLR were age <60, prior PCI, unprotected left main PCI, saphenous vein graft PCI, minimum stent diameter < or =2.5 mm, and total stent length > or =40 mm. Comparison of observed versus predicted rates of TLR according to risk score demonstrated good model fit in the validation set. There was more than a 3-fold difference in TLR rates between the lowest risk category (score=0; TLR rate, 2.2%) and the highest risk category (score > or =5; TLR rate, 7.5%).
CONCLUSIONS: The overall incidence of TLR remains low among unselected patients receiving DES in routine clinical practice. A simple risk model incorporating 6 readily available clinical and angiographic variables helps identify individuals at extremely low (<2%) and modestly increased (>7%) risk of TLR after DES implantation.

Entities:  

Mesh:

Year:  2010        PMID: 20606136     DOI: 10.1161/CIRCINTERVENTIONS.110.946939

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  23 in total

Review 1.  Restenosis after PCI. Part 2: prevention and therapy.

Authors:  J Wouter Jukema; Tarek A N Ahmed; Jeffrey J W Verschuren; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2011-10-11       Impact factor: 32.419

2.  A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study).

Authors:  Jacek Legutko; Wojciech Zasada; Grzegorz L Kałuża; Grzegorz Heba; Lukasz Rzeszutko; Jacek Jakala; Jacek Dragan; Artur Klecha; Dawid Giszterowicz; Wojciech Dobrowolski; Lukasz Partyka; Swaminathan Jayaraman; Dariusz Dudek
Journal:  Indian Heart J       Date:  2013-07-21

3.  Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.

Authors:  Maayan Konigstein; Mahesh V Madhavan; Ori Ben-Yehuda; Hussein M Rahim; Iva Srdanovic; Fotis Gkargkoulas; Ghazaleh Mehdipoor; Evan Shlofmitz; Akiko Maehara; Björn Redfors; Ankita K Gore; Thomas McAndrew; Gregg W Stone; Ziad A Ali
Journal:  Am Heart J       Date:  2019-04-12       Impact factor: 4.749

Review 4.  Postoperative care and follow-up after coronary stenting.

Authors:  Tienush Rassaf; Stephan Steiner; Malte Kelm
Journal:  Dtsch Arztebl Int       Date:  2013-02-01       Impact factor: 5.594

5.  Resolute zotarolimus eluting stent for treatment of long coronary lesions.

Authors:  Martin Rothman
Journal:  Indian Heart J       Date:  2015-06-13

Review 6.  Restenosis after PCI. Part 1: pathophysiology and risk factors.

Authors:  J Wouter Jukema; Jeffrey J W Verschuren; Tarek A N Ahmed; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2011-09-13       Impact factor: 32.419

7.  Clinical presentation and predictors of target vessel revascularization after drug-eluting stent implantation.

Authors:  Hazem Al Muradi; Aditya Mehra; Joseph Okolo; Helen Vlachos; Faith Selzer; Oscar C Marroquin; Kimberly Skelding; Elizabeth M Holper; David O Williams; J Dawn Abbott
Journal:  Cardiovasc Revasc Med       Date:  2012 Nov-Dec

8.  Predicting target vessel revascularization in older patients undergoing percutaneous coronary intervention in the drug-eluting stent era.

Authors:  Connie N Hess; Sunil V Rao; David Dai; Megan L Neely; Robert N Piana; John C Messenger; Eric D Peterson
Journal:  Am Heart J       Date:  2014-01-04       Impact factor: 4.749

9.  The 'all comer' Coroflex Please drug-eluting stent registry in Europe and Asia - an overall and transcontinental assessment of the 10-month major adverse cardiac events.

Authors:  Matthias Leschke; Vo Thanh Nhan; Matthias Waliszewski; Vicente Palacios; Iván Horváth; Vladimir A Ivanov; Damras Tresukosol; Panicos Avraamides; André Schneider; Martin Unverdorben
Journal:  Indian Heart J       Date:  2012-08-27

10.  Epac1 deficiency inhibits basic fibroblast growth factor-mediated vascular smooth muscle cell migration.

Authors:  Yuko Kato; Utako Yokoyama; Takayuki Fujita; Masanari Umemura; Tetsuo Kubota; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2018-08-06       Impact factor: 2.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.